

Andreas Rimner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2976453/publications.pdf>

Version: 2024-02-01

152
papers

6,189
citations

81839

39
h-index

85498

71
g-index

153
all docs

153
docs citations

153
times ranked

6843
citing authors

#	ARTICLE	IF	CITATIONS
1	CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors. <i>Annals of Thoracic Surgery</i> , 2022, 113, 957-965.	0.7	12
2	A Planning Comparison of IMRT vs. Pencil Beam Scanning for Deep Inspiration Breath Hold Lung Cancers. <i>Medical Dosimetry</i> , 2022, 47, 26-31.	0.4	2
3	Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2022, 167, 158-164.	0.3	10
4	New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 681-692.	0.8	26
5	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
6	Four-Dimensional Computed Tomography-Based Correlation of Respiratory Motion of Lung Tumors With Implanted Fiducials and an External Surrogate. <i>Advances in Radiation Oncology</i> , 2022, 7, 100885.	0.6	6
7	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	8
8	Thymic Carcinomas—A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. <i>Journal of Thoracic Oncology</i> , 2022, 17, 637-650.	0.5	18
9	Can bronchoscopically implanted anchored electromagnetic transponders be used to monitor tumor position and lung inflation during deep inspiration breath-hold lung radiotherapy?. <i>Medical Physics</i> , 2022, 49, 2621-2630.	1.6	3
10	Deep learning driven predictive treatment planning for adaptive radiotherapy of lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 169, 57-63.	0.3	4
11	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	0.9	5
12	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	1.4	11
13	Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614.	1.9	2
14	Optimizing Lung Cancer Radiotherapy Treatments Using Personalized Dose-Response Curves. <i>Medical Radiology</i> , 2022, , .	0.0	0
15	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 35-52.	0.4	54
16	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38
17	Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. <i>Clinical Imaging</i> , 2021, 69, 133-138.	0.8	1
18	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100615.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy. <i>Practical Radiation Oncology</i> , 2021, 11, e52-e62.	1.1	18
20	Feasibility of MR-guided radiotherapy using beam-eye-view 2D-cine with tumor-volume projection. <i>Physics in Medicine and Biology</i> , 2021, 66, 045020.	1.6	5
21	Evolution of systemic therapy for stages Iâ€“III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	12.5	152
22	What Is the Impact of Hippocampus Avoidanceâ€“Prophylactic Cranial Irradiation on Neurocognitive Preservation?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 722-724.	0.5	1
23	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLCâ€“an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	0.5	323
24	Deep crossâ€“modality (MRâ€“CT) educed distillation learning for cone beam CT lung tumor segmentation. <i>Medical Physics</i> , 2021, 48, 3702-3713.	1.6	9
25	In Reply to Sabour. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 915-916.	0.4	0
26	Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100197.	0.6	3
27	Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. <i>Cancers</i> , 2021, 13, 3734.	1.7	7
28	Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 883-892.	0.4	10
29	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. <i>Nature Communications</i> , 2021, 12, 4669.	5.8	19
30	Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100209.	0.6	7
31	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1392-1402.	0.5	12
32	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17
33	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	5.9	23
34	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5773.	1.7	0
35	Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer. <i>Medical Radiology</i> , 2021, , .	0.0	0
36	Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy. <i>Acta OncolÃ³gica</i> , 2020, 59, 164-170.	0.8	14

#	ARTICLE	IF	CITATIONS
37	LDeform: Longitudinal deformation analysis for adaptive radiotherapy of lung cancer. <i>Medical Physics</i> , 2020, 47, 132-141.	1.6	5
38	Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?. <i>Radiotherapy and Oncology</i> , 2020, 143, 51-57.	0.3	16
39	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 705-714.e1.	0.4	18
40	Technical Note: 3D localization of lung tumors on cone beam CT projections via a convolutional recurrent neural network. <i>Medical Physics</i> , 2020, 47, 1161-1166.	1.6	8
41	The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 436-447.	0.5	46
42	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 144, 101-104.	0.3	21
43	Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors. <i>Lung Cancer</i> , 2020, 147, 45-48.	0.9	27
44	Enhanced super-resolution reconstruction of T1w time-resolved 4DMRI in low-contrast tissue using 2-step hybrid deformable image registration. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 25-39.	0.8	8
45	Predictive Modeling of Thoracic Radiotherapy Toxicity and the Potential Role of Serum Alpha-2-Macroglobulin. <i>Frontiers in Oncology</i> , 2020, 10, 1395.	1.3	6
46	Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review. <i>Radiation Oncology</i> , 2020, 15, 214.	1.2	103
47	Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. <i>Cancer Medicine</i> , 2020, 9, 4622-4631.	1.3	37
48	A super-resolution framework for the reconstruction of T2-weighted (T2w) time-resolved (TR) 4DMRI using T1w TR-4DMRI as the guidance. <i>Medical Physics</i> , 2020, 47, 3091-3102.	1.6	9
49	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.4	40
50	Cardio-pulmonary substructure segmentation of radiotherapy computed tomography images using convolutional neural networks for clinical outcomes analysis. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 61-66.	1.2	38
51	Quantification of accumulated dose and associated anatomical changes of esophagus using weekly Magnetic Resonance Imaging acquired during radiotherapy of locally advanced lung cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 13, 36-43.	1.2	18
52	Delivering safe and effective stereotactic body radiation therapy for patients with centrally located early stage non-small cell lung cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 39-39.	0.4	5
53	Clinical outcomes, local/regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
54	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.3	168

#	ARTICLE	IF	CITATIONS
55	Thoracic Radiation Therapy During Coronavirus Disease 2019: Provisional Guidelines from a Comprehensive Cancer Center within a Pandemic Epicenter. <i>Advances in Radiation Oncology</i> , 2020, 5, 603-607.	0.6	14
56	Need for Caution in the Diagnosis of Radiation Pneumonitis During the COVID-19 Pandemic. <i>Advances in Radiation Oncology</i> , 2020, 5, 617-620.	0.6	12
57	Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1613-1613.	0.7	0
58	Predicting spatial esophageal changes in a multimodal longitudinal imaging study via a convolutional recurrent neural network. <i>Physics in Medicine and Biology</i> , 2020, 65, 235027.	1.6	7
59	Toward predicting the evolution of lung tumors during radiotherapy observed on a longitudinal MR imaging study via a deep learning algorithm. <i>Medical Physics</i> , 2019, 46, 4699-4707.	1.6	34
60	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1172-1183.	0.5	60
61	Cross-modality (CT-MRI) prior augmented deep learning for robust lung tumor segmentation from small MR datasets. <i>Medical Physics</i> , 2019, 46, 4392-4404.	1.6	42
62	Dose to the cardio-pulmonary system and treatment-induced electrocardiogram abnormalities in locally advanced non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 96-102.	0.9	16
63	Clinical evaluation of 4D MRI in the delineation of gross and internal tumor volumes in comparison with 4DCT. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 51-60.	0.8	17
64	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1989-1994.	0.5	10
65	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee and International Association for the Study of Lung Cancer Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	0.5	15
66	Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 169-188.	0.8	4
67	Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy. <i>European Radiology</i> , 2019, 29, 3696-3704.	2.3	1
68	Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models. <i>Radiotherapy and Oncology</i> , 2019, 138, 45-51.	0.3	27
69	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. <i>Cancer Immunology Research</i> , 2019, 7, 1047-1053.	1.6	59
70	Enhancement of Long-Term External-Internal Correlation by Phase-Shift Detection and Correction Based on Concurrent External Bellows and Internal Navigator Signals. <i>Advances in Radiation Oncology</i> , 2019, 4, 377-389.	0.6	6
71	The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group. <i>Lung Cancer</i> , 2019, 132, 24-27.	0.9	9
72	Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors. <i>JAMA Oncology</i> , 2019, 5, 737.	3.4	24

#	ARTICLE	IF	CITATIONS
73	Segmenting lung tumors on longitudinal imaging studies via a patient-specific adaptive convolutional neural network. <i>Radiotherapy and Oncology</i> , 2019, 131, 101-107.	0.3	27
74	A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 5187-5198.	0.6	32
75	Outcomes of Stage III NSCLC with occult primary vs. known primary lesions. <i>Lung Cancer</i> , 2019, 127, 34-36.	0.9	2
76	Diffusion-weighted MRI of the lung at 3T evaluated using echo-planar based and single-shot turbo spin-echo based acquisition techniques for radiotherapy applications. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 284-292.	0.8	13
77	A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 362-373.e8.	0.4	57
78	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	3.0	96
79	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. <i>Journal of Clinical Investigation</i> , 2019, 129, 786-801.	3.9	50
80	Radiomics analysis of pulmonary nodules in low-dose CT for early detection of lung cancer. <i>Medical Physics</i> , 2018, 45, 1537-1549.	1.6	104
81	The value of collaboration between thoracic surgeons and radiation oncologists while awaiting evidence in operable stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 429-431.	0.4	8
82	Identifying the Optimal Radiation Dose in Locally Advanced Non-small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e131-e140.	1.1	10
83	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1343-1373.	0.8	324
84	The expanding role of radiation therapy for thymic malignancies. <i>Journal of Thoracic Disease</i> , 2018, 10, S2555-S2564.	0.6	19
85	Evaluation of automatic contour propagation in T2-weighted 4D MRI for normal tissue motion assessment using internal organ-at-risk volume (IRV). <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 598-608.	0.8	9
86	Design and validation of a MV/kV imaging-based markerless tracking system for assessing real-time lung tumor motion. <i>Medical Physics</i> , 2018, 45, 5555-5563.	1.6	16
87	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
88	Tumor-Aware, Adversarial Domain Adaptation from CT to MRI for Lung Cancer Segmentation. <i>Lecture Notes in Computer Science</i> , 2018, 11071, 777-785.	1.0	104
89	Correlation Between Tumor Metabolism and Semiquantitative Perfusion Magnetic Resonance Imaging Metrics in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 718-726.	0.4	12
90	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. <i>Advances in Radiation Oncology</i> , 2018, 3, 391-398.	0.6	33

#	ARTICLE	IF	CITATIONS
91	Validating a Predictive Atlas of Tumor Shrinkage for Adaptive Radiotherapy of Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 978-986.	0.4	16
92	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 848-855.	0.7	17
93	Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). <i>Acta Oncologica</i> , 2018, 57, 1567-1573.	0.8	51
94	Pharmacokinetic Analysis of Dynamic ¹⁸ F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 911-919.	2.8	22
95	Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, e161-e168.	1.1	17
96	Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 409-418.	0.4	87
97	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.4	19
98	Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 295-301.	1.1	339
99	Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2017, 108, 109-114.	0.9	36
100	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.	0.5	53
101	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1066-1076.	0.4	19
102	Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. <i>Journal of Thoracic Oncology</i> , 2017, 12, 745-751.	0.5	23
103	A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning. <i>Physics in Medicine and Biology</i> , 2017, 62, 702-714.	1.6	15
104	Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 548-554.	0.6	36
105	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	3.2	48
106	Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. <i>Radiotherapy and Oncology</i> , 2017, 125, 130-135.	0.3	37
107	Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 138-145.	0.4	43
108	PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT). <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 91-93.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479.	0.7	11
110	Palliative efficacy and local control of conventional radiotherapy for lung metastases. <i>Annals of Palliative Medicine</i> , 2017, 6, S21-S27.	0.5	11
111	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	1.1	54
112	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.	0.8	31
113	Characterization of optical surface imaging-based spirometry for respiratory surrogating in radiotherapy. <i>Medical Physics</i> , 2016, 43, 1348-1360.	1.6	19
114	Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. <i>Lancet Oncology</i> , The, 2016, 17, e43-e44.	5.1	28
115	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1357-1366.	0.4	134
116	SMART or simply bold?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 476-477.	0.4	5
117	Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 766-771.	0.6	52
118	Postoperative Radiation Therapy Is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma—An Analysis of the International Thymic Malignancies Interest Group Retrospective Database. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1785-1792.	0.5	82
119	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. <i>EJNMMI Research</i> , 2016, 6, 79.	1.1	25
120	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	0.8	154
121	Prognostic Value of Preradiotherapy 18F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 184-188.	1.1	17
122	High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins. <i>Brachytherapy</i> , 2016, 15, 208-215.	0.2	3
123	Quantitative assessment of target delineation variability for thymic cancers: agreement evaluation of a prospective segmentation challenge. <i>Journal of Radiation Oncology</i> , 2016, 5, 55-61.	0.7	4
124	Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. <i>Clinical Lung Cancer</i> , 2016, 17, 177-183.e2.	1.1	57
125	Novel spirometry based on optical surface imaging. <i>Medical Physics</i> , 2015, 42, 1690-1697.	1.6	19
126	Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy. <i>Clinical Imaging</i> , 2015, 39, 254-258.	0.8	19

#	ARTICLE	IF	CITATIONS
127	Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 418-424.	0.4	20
128	Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e253-e258.	1.1	28
129	Postoperative radiotherapy: Not all thymic malignancies are created equal. <i>Cancer</i> , 2015, 121, 972-974.	2.0	5
130	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 935-944.	0.4	83
131	Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2100-2105.	0.8	150
132	FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 115-120.	0.9	53
133	Thymic carcinoma outcomes and prognosis: Results of an international analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 95-101.e2.	0.4	190
134	Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 103-109.e2.	0.4	96
135	Local Control and Toxicity in a Large Cohort of Central Lung Tumors Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1168-1176.	0.4	98
136	Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: A feasibility study. <i>Medical Physics</i> , 2014, 41, 071906.	1.6	22
137	Evaluation of tumor localization in respiration motion-corrected cone-beam CT: Prospective study in lung. <i>Medical Physics</i> , 2014, 41, 101918.	1.6	12
138	Rapid estimation of 4DCT motion artifact severity based on 1D breathing surrogate periodicity. <i>Medical Physics</i> , 2014, 41, 111717.	1.6	18
139	Failure Patterns Relative to Radiation Treatment Fields for Stage II-IV Thymoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 403-409.	0.5	38
140	Predictive Treatment Management: Incorporating a Predictive Tumor Response Model Into Robust Prospective Treatment Planning for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 446-452.	0.4	30
141	Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. <i>Radiotherapy and Oncology</i> , 2014, 112, 267-271.	0.3	53
142	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.4	55
143	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 322-329.	0.4	91
144	ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. <i>Oncology</i> , 2014, 28, 706-10, 712, 714 passim.	0.4	22

#	ARTICLE	IF	CITATIONS
145	Toward correcting drift in target position during radiotherapy via computer-controlled couch adjustments on a programmable Linac. <i>Medical Physics</i> , 2013, 40, 051719.	1.6	13
146	Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1278-1283.	0.4	142
147	Novel radiation therapy approaches in malignant pleural mesothelioma. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 457-61.	0.6	24
148	Multidisciplinary Management of Thymic Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 466-470.	1.8	1
149	Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. <i>Cancer</i> , 2009, 115, 149-157.	2.0	43
150	Palliative Radiation for Lung Cancer Metastases to the Breast: Two Case Reports. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1133-1135.	0.5	9
151	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 178-185.	1.3	21
152	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. <i>Translational Lung Cancer Research</i> , 2007, 6, 186-195.	1.3	13